CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated

Anti-CD19 chimeric antigen receptor (CAR)-T cells have improved the outcomes of patients with B cell leukemia and lymphoma. However, their applications and positive outcomes remain limited. CAR-T cells are currently restricted to autologous blood as their source and their use can lead to downregulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyori, Han, Mina, Kim, Minsong, Kim, Hyeri, Im, Ho Joon, Kim, Nayoung, Koh, Kyung-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161343/
https://www.ncbi.nlm.nih.gov/pubmed/37153038
http://dx.doi.org/10.3892/ol.2023.13822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161343/
https://www.ncbi.nlm.nih.gov/pubmed/37153038
http://dx.doi.org/10.3892/ol.2023.13822

Ejemplares similares